Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
// Joseph J. Sacco 1 , Jenna Kenyani 1 , Zohra Butt 1 , Rachel Carter 1 , Hui Yi Chew 1, 2 , Liam P. Cheeseman 1, 3 , Sarah Darling 1 , Michael Denny 1 , Sylvie Urbé 1 , Michael J. Clague 1 , Judy M. Coulson 1 1 Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK 2 Current address: Cancer Stem Cell Biology, Agency for Science Technology and Research, Genome Institute of Singapore, Singapore 3 Current address: MRC Laboratory of Molecular Biology, Cambridge, UK Correspondence to: Judy M. Coulson, e-mail: j.m.coulson@liv.ac.uk Keywords: histone deacetylase 2, BRCA1-associated protein 1, MPM, vorinostat, stratified medicine Received: October 31, 2014 Accepted: April 10, 2015 Published: April 24, 2015 ABSTRACT Histone deacetylases are important targets for cancer therapeutics, but their regulation is poorly understood. Our data show coordinated transcription of HDAC1 and HDAC2 in lung cancer cell lines, but suggest HDAC2 protein expression is cell-context specific. Through an unbiased siRNA screen we found that BRCA1-associated protein 1 (BAP1) regulates their expression, with HDAC2 reduced and HDAC1 increased in BAP1 depleted cells. BAP1 loss-of-function is increasingly reported in cancers including thoracic malignancies, with frequent mutation in malignant pleural mesothelioma. Endogenous HDAC2 directly correlates with BAP1 across a panel of lung cancer cell lines, and is downregulated in mesothelioma cell lines with genetic BAP1 inactivation. We find that BAP1 regulates HDAC2 by increasing transcript abundance, rather than opposing its ubiquitylation. Importantly, although total cellular HDAC activity is unaffected by transient depletion of HDAC2 or of BAP1 due to HDAC1 compensation, this isoenzyme imbalance sensitizes MSTO-211H cells to HDAC inhibitors. However, other established mesothelioma cell lines with low endogenous HDAC2 have adapted to become more resistant to HDAC inhibition. Our work establishes a mechanism by which BAP1 loss alters sensitivity of cancer cells to HDAC inhibitors. Assessment of BAP1 and HDAC expression may ultimately help identify patients likely to respond to HDAC inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566 · cited 1×
“This is not unusual, in fact global studies report that the major determinant of protein abundance is neither transcription nor protein degradation, but is instead translation [45].”
BackgroundRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“In fact, somatic BAP1 mutation occurs in only around 1% of lung adenocarcinoma [23, 24], but is far more prevalent in uveal melanoma [25, 26], mesothelioma [18, 19] and renal clear cell carcinoma [27].”
BackgroundCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 1×
“A notable exception was the NCI-H2052 cell line, which has loss of HDAC2 copy number (COSMIC, [21]) that likely accounts for low expression of HDAC2 even in the presence of BAP1.”
BackgroundThatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076
Bott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg315 · Cited by 523 · cited 1×
“In the setting of reversible ubiquitylation, alternative ubiquitin E3 ligases have been identified for HDAC1 [7, 8] and HDAC2 [9, 10], which either modulate their transcriptional activity or target them for proteasomal degradation, but no deubiquitylases (DUBs) have yet been identified that antagonize these functions.”
BackgroundThe deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1
Machida, Y. J., Machida, Y., Vashisht, A. A., Wohlschlegel, J. A., & Dutta, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.046755 · Cited by 274 · cited 2×
“In several studies, BAP1 loss is in fact reported to slow cell growth through a delayed but more permissive G1/S cell cycle checkpoint [19, 40].”
BackgroundGermline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma
Xu, J., Kadariya, Y., Cheung, M., Pei, J., Talarchek, J., Sementino, E., Tan, Y., Menges, C. W., Cai, K. Q., Litwin, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1328 · Cited by 144 · cited 3×
“Up to 80% of mesothelioma are directly attributable to asbestos exposure [47] and it was recently shown that mice with heterozygous germline BAP1 knockout were predisposed to develop mesothelioma upon asbestos exposure [48].”
Background
Research works printed but not linked: 50
- Mann, 2009, Lysine acetylation targets protein complexes and co-regulates major cellular functions, Science, 325, 834, 10.1126/science.1175371 · DOI · Paper page
- Chabner, 2009, Histone deacetylase inhibitors in cancer therapy, J Clin Oncol, 27, 5459, 10.1200/JCO.2009.22.1291 · DOI · Paper page
- Seiser, 2014, Transcription and beyond: the role of mammalian class I lysine deacetylases, Chromosoma, 123, 67, 10.1007/s00412-013-0441-x · DOI
- Chiocca, 2007, Role for histone deacetylase 1 in human tumor cell proliferation, Mol Cell Biol, 27, 4784, 10.1128/MCB.00494-07 · DOI · Paper page
- Rahman, 2009, Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke, Am J Respir Cell Mol Biol, 40, 464, 10.1165/rcmb.2008-0255OC · DOI · Paper page
- Chiocca, 2011, Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2, J Biomed Biotechnol, 2011, 690848
- Robson, 2005, Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation, Nucleic Acids Res, 33, 13, 10.1093/nar/gki141 · DOI · Paper page
- Seol, 2009, Chfr is linked to tumour metastasis through the downregulation of HDAC1, Nat Cell Biol, 11, 295, 10.1038/ncb1837 · DOI
- Zhong, 2011, Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2, Genes Dev, 25, 2610, 10.1101/gad.170605.111 · DOI
- Marks, 2007, Discovery and development of SAHA as an anticancer agent, Oncogene, 26, 1351, 10.1038/sj.onc.1210204 · DOI · Paper page
- Natoli, 2013, Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies, Cancers, 5, 919, 10.3390/cancers5030919 · DOI
- Wright, 2012, Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer, Pharmaceutical patent analyst, 1, 207, 10.4155/ppa.12.21 · DOI
- Coulson, 2014, The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells, Oncogene, 33, 4265, 10.1038/onc.2013.512 · DOI · Paper page
- Coulson, 2013, The deubiquitylase USP15 stabilizes newly synthesized REST and rescues its expression at mitotic exit, Cell Cycle, 12, 1964, 10.4161/cc.25035 · DOI
- Hasegawa, 2012, Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma, Cancer Sci, 103, 868, 10.1111/j.1349-7006.2012.02223.x · DOI · Paper page
- Friedberg, 2012, BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs, J Transl Med, 10, 179, 10.1186/1479-5876-10-179 · DOI · Paper page
- Therrien, 2014, Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O, Mol Cell, 54, 392, 10.1016/j.molcel.2014.03.002 · DOI · Paper page
- Schultz, 1998, BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression, Oncogene, 16, 1097, 10.1038/sj.onc.1201861 · DOI · Paper page
- Goldstein, 2011, Germline BAP1 mutations and tumor susceptibility, Nat Genet, 43, 925, 10.1038/ng.956 · DOI
- Pirun, 2011, Germline mutations in BAP1 predispose to melanocytic tumors, Nat Genet, 43, 1018, 10.1038/ng.910 · DOI · Paper page
- Bowcock, 2010, Frequent mutation of BAP1 in metastasizing uveal melanomas, Science, 330, 1410, 10.1126/science.1194472 · DOI · Paper page
- Zhao, 2011, Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma, Nat Genet, 44, 17
- Davidorf, 2011, Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers, J Med Genet, 48, 856, 10.1136/jmedgenet-2011-100156 · DOI · Paper page
- Gyapay, 2013, Germline BAP1 mutations predispose to renal cell carcinomas, Am J Hum Genet, 92, 974, 10.1016/j.ajhg.2013.04.012 · DOI · Paper page
- Scolyer, 2013, Tumours associated with BAP1 mutations, Pathology, 45, 116
- Shen, 2012, BAP1 is a good prognostic factor in advanced non-small cell lung cancer, Clin Invest Med, 35, E182, 10.25011/cim.v35i4.17146 · DOI
- Kang, 2013, Prognostic significance of BRCA1-associated protein 1 in colorectal cancer, Med Oncol, 30, 541, 10.1007/s12032-013-0541-8 · DOI
- Murali, 2013, BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma, Pathology, 45, 651
- Lotan, 2014, BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma, J Urol, 191, 603, 10.1016/j.juro.2013.09.041 · DOI
- Parker, 2014, Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma, Cancer, 120, 1059, 10.1002/cncr.28521 · DOI · Paper page
- Popper, 2014, BAP1 protein is a progression factor in malignant pleural mesothelioma, Pathol Oncol Res, 20, 145, 10.1007/s12253-013-9677-2 · DOI
- Coupland, 2014, Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing, Br J Cancer, 111, 1373, 10.1038/bjc.2014.417 · DOI · Paper page
- Muller, 2010, Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB, Nature, 465, 243, 10.1038/nature08966 · DOI · Paper page
- Wilson, 2009, Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1, Mol Cell Biol, 29, 2181, 10.1128/MCB.01517-08 · DOI · Paper page
- Harper, 2009, Defining the human deubiquitinating enzyme interaction landscape, Cell, 138, 389, 10.1016/j.cell.2009.04.042 · DOI · Paper page
- Katavolos, 2012, Loss of the tumor suppressor BAP1 causes myeloid transformation, Science, 337, 1541, 10.1126/science.1221711 · DOI · Paper page
- Brosch, 2013, Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis, EMBO J, 32, 3176, 10.1038/emboj.2013.243 · DOI · Paper page
- Seiser, 2011, Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis, Cell Cycle, 10, 406, 10.4161/cc.10.3.14712 · DOI · Paper page
- Ladanyi, 2013, Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations, J Thorac Oncol., 8, 1430, 10.1097/JTO.0b013e31829e7ef9 · DOI · Paper page
- Testa, 2002, The pathogenesis of mesothelioma, Semin Oncol, 29, 2, 10.1053/sonc.2002.30227 · DOI · Paper page
- Harbour, 2013, BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma, BMC Cancer, 13, 371, 10.1186/1471-2407-13-371 · DOI
- Petel, 2014, Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition, Clin Cancer Res, 20, 1323, 10.1158/1078-0432.CCR-13-2429 · DOI · Paper page
- Santoro, 2009, Future developments in the management of malignant pleural mesothelioma, Expert Rev Anticancer Ther, 9, 453, 10.1586/era.09.2 · DOI
- Smith, 2005, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917, 10.1038/nature03445 · DOI · Paper page
- Di Noia, 2014, Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair, Proc Natl Acad Sci U S A, 111, 285, 10.1073/pnas.1309085110 · DOI · Paper page
- Olgac, 2005, Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer, J Clin Oncol, 23, 3923, 10.1200/JCO.2005.14.167 · DOI · Paper page
- Krug, 2012, Novel therapies in phase II and III trials for malignant pleural mesothelioma, J Natl Compr Canc Netw, 10, 42, 10.6004/jnccn.2012.0007 · DOI
- Yang, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699 · DOI · Paper page
- Harbour, 2012, Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma, Clin Cancer Res, 18, 408, 10.1158/1078-0432.CCR-11-0946 · DOI · Paper page
- Coulson, 2009, SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer, Clin Cancer Res, 15, 274, 10.1158/1078-0432.CCR-08-1163 · DOI
Cited by
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 345
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1220 · Cited by 287
“Upon BAP1 loss, HDAC1 is increased and HDAC2 is reduced, an effect that was observed across several lung cancer and mesothelioma cell lines (134).”
BackgroundThe PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
Ny, L., Jespersen, H., Karlsson, J., Alsén, S., Filges, S., All-Eriksson, C., Andersson, B., Carneiro, A., Helgadottir, H., Levin, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25332-w · Cited by 177
Biological Basis for Novel Mesothelioma Therapies
Obacz, J., Yung, H., Shamseddin, M., Linnane, E., Liu, X., Azad, A. A., Rassl, D. M., Fairen-Jimenez, D., Rintoul, R. C., Nikolić, M. Z., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01462-2 · Cited by 31
Metadata
- Authors
- Sacco, J. J., Kenyani, J., Butt, Z., Carter, R., Chew, H. Y., Cheeseman, L. P., Darling, S., Denny, M., Urbé, S., Clague, M. J., & Coulson, J. M.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-04-24
- Volume
- 6
- Issue
- 15
- Pages
- 13757-13771
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1961955832
- Cited by
- 59
- References
- 10
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.